NCT06504446

Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Taplucainium Inhalation Powder (NOC-110) in Adults With Refractory or Unexplained Chronic Cough

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 455 (estimated)
• Sponsor: Nocion Therapeutics · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This is a phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of Taplucainium Inhalation Powder (NOC-110) once daily in adults with refractory or unexplained chronic cough.

Detailed description

Approximately 455 participants will take part in the study. It is anticipated that up to 1264 participants will be screened. Participation will be approximately 13 weeks.

Conditions

• Refractory or Unexplained Chronic Cough

Interventions

Type	Name	Description
DRUG	NOC-110	Inhalation powder
OTHER	Placebo	Inhalation powder

Timeline

• Start date: 2024-09-24
• Primary completion: 2026-04-10
• Completion: 2026-04-10
• First posted: 2024-07-16
• Last updated: 2026-02-17

Locations

107 sites across 6 countries: United States, Belgium, Canada, Germany, Poland, United Kingdom

Regulatory

• FDA-regulated drug study